• CEVEC Pharmaceuticals

  Participated · Equity · Nov 2009

  CEVEC develops proprietary cell line technologies—notably ELEVECTA® for stable AAV production and CAP® for RCA-free adenoviral production—targeting scalable viral vector and complex protein manufacturing. The company’s ELEVECTA® approach uses producer cells with stably integrated components, enabling helper-virus-free, suspension-based AAV production without expensive transfection reagents or cGMP plasmids. CEVEC is implementing ELEVECTA® in HEK293 as a second host cell type to address common gene-therapy manufacturing workflows. The firm also offers CAP-Go® for recombinant production of complex glycosylated proteins and CAP® for adenoviral, lentiviral, vaccine and exosome production. Management says the company was profitable in 2020 and plans to use new funds to accelerate growth and expand cell line development capacities to meet rising demand. The company is based in Cologne, Germany. CEVEC is an expert in production of tailor-made recombinant glycoproteins and gene therapy vectors using a unique human cell–based expression system. Its CAP®GT platform includes suspension cell–derived viral packaging cell lines and a stable, helper virus–free AAV production platform designed to enable industrial-scale AAV manufacturing. The company positions itself as the first to make AAV production as straightforward as monoclonal antibody production and is upscaling the platform to industrial scale while commercializing with leading gene therapy partners. CEVEC’s stable AAV system uses chemically inducible producer cell lines rather than multiple transient transfections, aiming for more robust, reproducible and cost‑efficient manufacturing. CEVEC also offers the CAP®Go platform for producing complex glycosylated proteins and plans to expand its stable vector portfolio to include lentiviral, adenoviral and other vectors. The company announced a Series D financing round to fund the industrial scale‑up and commercialization of CAP®GT and to broaden its technology portfolio. Cevec Pharmaceuticals GmbH is a Cologne, Germany–based producer of tailor-made recombinant glycoproteins and gene therapy vectors built on a unique human cellular expression system. The company has developed and recently introduced two platforms: CAP(R)Go and CAP(R)GT. CAP(R)Go is a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. Its panel of cell lines differs in glycosylation capabilities and enables production of complexly glycosylated proteins such as cytokines, ion channels, virus envelope proteins, coagulation factors and other plasma proteins. CAP(R)GT provides a regulatory-endorsed production system for gene therapy vectors and supports lentiviral (LV), adenoviral (AV) and adeno-associated viral (AAV) vectors. Cevec completed a €4.5m financing round and intends to use the funds to further develop the CAP(R)Go and CAP(R)GT platforms. CEVEC Pharmaceuticals develops and produces therapeutic proteins, vaccines and monoclonal antibodies using proprietary human cell expression systems that yield human glycosylation patterns. The company has developed proprietary and patent-protected CAP® and CAP-T™ expression systems designed to manufacture complex biopharmaceutical molecules and various vaccines. It licenses its human cell-based expression platform and its own Biobetter candidates through partnerships with pharmaceutical and biotech companies. CEVEC intends to use the funds from the recent financing to continue growing its protein and vaccine commercialization business based on its CAP® Technology platform. The company also plans to develop additional vaccines together with partners contingent on a further financing round expected to close by the end of 2011. CEVEC is led by CEO Dr. Rainer Lichtenberger and CCO Wolfgang Kintzel. CEVEC Pharmaceuticals is a Cologne-based biopharmaceutical company that develops and produces therapeutic proteins and monoclonal antibodies with human glycosylation patterns. Its proprietary CAP Technology is used to produce complex biologics and therapeutic antibodies with human-like glycosylation and sialylation patterns. The company closed a €4m financing round to support its growth. Investors in the round were led by Creathor Venture Fonds and NRW.BANK and included current investors and a group of private and institutional investors such as the venture capital branch of Sparkasse KoelnBonn and ERP Startfonds of KfW bank. The funds will be used to continue the global commercialization of the CAP Technology platform. CEO Dr. Rainer Lichtenberger said the new investors provide the resources required to finance the company’s ambitious growth objectives.

No current team members are available.